Member Info for Jungmana

The US are the main drivers of the price here. They love NFT stocks over there and most peers are valued at £60m market cap or more.
Today's market cap is just about £18m at 12p

Should be worth today at least 5 times whatever vlrm are worth.
The cash and Crypto treasury here alone are worth more than $3million today. Partnership with big blockchain players Indorse, redfox etc. Owns lots of NFT's and nifty lab jv with Indorse. Gibraltar crypto stamp sale on 17th of May followed by NFT sales. Excellent experience management in the sector.
Exciting 3 to 6 weeks ahead here and could see us past the recent high of 38p

13p equivalent in USA, good rebound as seller looks like is cleared. Too oversold at £15m market cap today when crap stocks in the sector such as vlrm is £18m market cap.
Anyway let's get back to 20p+ first.

Did this lot achieve anything with Upper Thames holding? NO all they have done is change the name and business. Raised 500k at 1p and ride the crypto mania.
Buy a few computers for $110k that can't even mine 2 Bitcoins in a year .
Vinay is just attached as an adviser to give themselves some credibility.
Hype and speculation is what drove this but barely any tangible value created so far.
Good luck punters

Tell your prophet Lenigas to stop comparing this rubbish to ARB on twitter then.
He thinks we are all fools to fall for his nonsense

You will do well to mine 2 Bitcoins in a year with the capacity just purchased.
Anyway hype and speculation can work wonders

Compared to ARB based on assets and mining capacity, vlrm should be 3p share price today.
This is a joke of a share driven by Lenigas and Poulden to use the crypto mania to continue riding the gravy train.

They will do well to mine 2 Bitcoins in a year with the capacity they acquired.
The company should be 4p not 25p share price

Cash of less than 500k and computers bought for Bitcoin mining with a tiny capacity that will be lucky to mine 2 Bitcoins in a year. To be a serious miner they will need £5m+ to start with for the equipment's and infrastructure. ARB has spent over £50m in last 4 years to be where they are . Their capacity is a 1000 times bigger than what vlrm just announced.
As for NFT's you will be lucky yo make £50k on a few tokens.
This company is not worth £3m market cap ( 5 share price) today imo.

Sold another dog share and added here at 123p.
Am bullish on this stock.

O/t VLRM is just a vehicle for Poulden and Lenigas to continue to ride the gravy train with the huge interest in cryptos.
The company has less than 500k cash and their equipment bought for mining has a capacity of mining less than 3 Bitcoins in a year.
Is a total crap share that should be worth no more than a fifth of its present market cap imo.

Going blue soon . Just too oversold at 13p . Number 1 NFT stocks in London

Huge buys there

https://youtu.be/snevPPjkgkU

Take away the £35m of cash and market cap at 5p is just £15m. With the interest in this ipo and funds wanting yo invest here I believe this could rise quickly.
Excellent team behind the company

17 March 2021

For release: 07.00, 17 March 2021

Toople PLC

("Toople" or the "Company")

Trading update and PDMR Share Dealing

Toople PLC (LSE: TOOP), a provider of bespoke telecom services to UK SMEs, is pleased to provide the following trading update. Further to recently announced significant contract wins, monthly orders are continuing to grow and gross margins are materially higher than the pre-pandemic period. This has enabled monthly cash burn to be reduced by 60% compared with 2020 and this trend is expected to be sustained, moving the Company towards positive cash flow. The Directors believe that trading will continue to demonstrate significant progress as the current UK lockdown begins to ease and the economy moves towards the post-pandemic period.

Boparan restaurant group, Age UK, Toca, A specialist nationwide engineering group and 5 other good sized companies all signed up in the last 4 months. Will they do so if we were rubbish?

"15 February 2021
For release: 07.00, 15(th) February 2021
Toople PLC
("Toople" or the "Company")
New contract wins with leading UK business brands
Toople PLC (LSE: TOOP), a provider of bespoke telecom services to UK SMEs, is pleased to announce five new contract wins with leading UK businesses across a variety of sectors."

1972, what you are likely to see here by summer is another acquisition similar to DMSL acquisition last year. By then the share price will be a lot higher imo
As the economy reopen s expect more contract news . There has been 6 good contracts signed over the last 3 months alone

Should see a test of the Oz closing price of 0.66p here this afternoon imo. May even go higher as sellers clear.
Am in about 0.40p

"Reasons for the Fundraising
In recent months, and as outlined in the announcement of 10 December 2020, Shield has developed a comprehensive plan for the self-commercialisation of Accrufer(R) in the US and the Placing and Subscription will provide significant funding to execute this plan. Sales estimates generated by management consultants and other third parties support the potential for sales of Accrufer(R) in the US to exceed $100 million from the third year following launch and to reach $300 million-$400 million by years five to six.
The Group's cash flow forecasts, including the costs of the US launch of Accrufer(R) and the paediatric study, indicate that the Group should start to breakeven on a monthly basis within 15-18 months after launch of the drug in the US provided sales and costs are within the range anticipated by the Directors . As previously announced, Shield believes that around $30 million to $40 million (c GBP21 million to GBP29 million) should provide the finance necessary to reach the breakeven point.
The net proceeds of the Subscription and the Placing will finance the launch costs of Accrufer(R). The bulk of the net proceeds received will be converted into US dollars promptly in order to avoid currency risk. US launch costs will include sales representatives, ongoing market research and data analysis, marketing spend and other US operational costs. The paediatric study and other non-US expenditure is expected to be partly funded out of gross margin generated by Shield in the US and Norgine BV royalty revenues.
The Group has assessed a range of other options to fund the US launch of Accrufer(R), including several debt and equity based financing solutions. However the Board believes that the funding requirements are best suited to an equity based financing solution which the Fundraising will provide. Further, the Directors believe that selling Accrufer(R) directly in the US has the potential to generate significant returns for Shareholders."

This company has potential to 10 bag over the coming 12 months. Wait till the payment app is launched and roll out across a few decent retailers and we could be in the top 5 soon